Mark E. Brady

956 total citations
17 papers, 732 citations indexed

About

Mark E. Brady is a scholar working on Nephrology, Pulmonary and Respiratory Medicine and Geriatrics and Gerontology. According to data from OpenAlex, Mark E. Brady has authored 17 papers receiving a total of 732 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Nephrology, 6 papers in Pulmonary and Respiratory Medicine and 5 papers in Geriatrics and Gerontology. Recurrent topics in Mark E. Brady's work include Frailty in Older Adults (5 papers), Dialysis and Renal Disease Management (5 papers) and Health Systems, Economic Evaluations, Quality of Life (4 papers). Mark E. Brady is often cited by papers focused on Frailty in Older Adults (5 papers), Dialysis and Renal Disease Management (5 papers) and Health Systems, Economic Evaluations, Quality of Life (4 papers). Mark E. Brady collaborates with scholars based in United Kingdom, Brazil and Australia. Mark E. Brady's co-authors include Susan Cook, David E. Neal, Craig Robson, Luke Gaughan, Ian Waite, Ian R. Logan, Vincent J. Gnanapragasam, Hing Y. Leung, Ajay Dhaygude and Neil Pendleton and has published in prestigious journals such as Journal of Biological Chemistry, PLoS ONE and Oncogene.

In The Last Decade

Mark E. Brady

17 papers receiving 724 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark E. Brady United Kingdom 10 460 218 171 79 76 17 732
Ulrich Tschulena Germany 13 524 1.1× 27 0.1× 53 0.3× 51 0.6× 18 0.2× 23 862
Stefano Mattarocci Switzerland 18 783 1.7× 25 0.1× 88 0.5× 119 1.5× 42 0.6× 27 982
Dany Gauthier Canada 12 215 0.5× 26 0.1× 44 0.3× 86 1.1× 62 0.8× 15 596
Kristine M. Wadosky United States 15 403 0.9× 236 1.1× 70 0.4× 96 1.2× 71 0.9× 25 631
Kazutoshi Yamana Japan 12 254 0.6× 247 1.1× 50 0.3× 115 1.5× 98 1.3× 38 543
Hisaichi Fujii Japan 20 355 0.8× 97 0.4× 151 0.9× 55 0.7× 23 0.3× 53 952
Seiji Arai Japan 17 285 0.6× 327 1.5× 68 0.4× 201 2.5× 141 1.9× 69 732
Rakhshanda Layeequr Rahman United States 15 213 0.5× 66 0.3× 88 0.5× 262 3.3× 35 0.5× 58 683
Verónica Rodríguez Italy 7 201 0.4× 95 0.4× 36 0.2× 37 0.5× 48 0.6× 10 339
Venke Skibeli Norway 8 123 0.3× 25 0.1× 29 0.2× 54 0.7× 43 0.6× 10 428

Countries citing papers authored by Mark E. Brady

Since Specialization
Citations

This map shows the geographic impact of Mark E. Brady's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark E. Brady with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark E. Brady more than expected).

Fields of papers citing papers by Mark E. Brady

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark E. Brady. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark E. Brady. The network helps show where Mark E. Brady may publish in the future.

Co-authorship network of co-authors of Mark E. Brady

This figure shows the co-authorship network connecting the top 25 collaborators of Mark E. Brady. A scholar is included among the top collaborators of Mark E. Brady based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark E. Brady. Mark E. Brady is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Floyd, Lauren, Adam Morris, Mark E. Brady, et al.. (2023). Low-Dose Intravenous Methylprednisolone in Remission Induction Therapy for ANCA-Associated Vasculitis. Kidney360. 4(9). e1286–e1292. 2 indexed citations
2.
Morris, Adam, Kássio M. G. Lima, Lauren Floyd, et al.. (2022). Automated Computational Detection of Disease Activity in ANCA-Associated Glomerulonephritis Using Raman Spectroscopy: A Pilot Study. Molecules. 27(7). 2312–2312. 6 indexed citations
3.
Morris, Adam, Camilo L. M. Morais, Kássio M. G. Lima, et al.. (2021). Distinguishing active from quiescent disease in ANCA-associated vasculitis using attenuated total reflection Fourier-transform infrared spectroscopy. Scientific Reports. 11(1). 9981–9981. 10 indexed citations
4.
Nixon, Andrew, Theodoros M. Bampouras, Hannah Young, et al.. (2021). Home-based exercise for people living with frailty and chronic kidney disease: A mixed-methods pilot randomised controlled trial. PLoS ONE. 16(7). e0251652–e0251652. 19 indexed citations
5.
Nixon, Andrew, Julie A. Brown, Ailsa Brotherton, et al.. (2020). Implementation of a frailty screening programme and Geriatric Assessment Service in a nephrology centre: a quality improvement project. Journal of Nephrology. 34(4). 1215–1224. 24 indexed citations
6.
Nixon, Andrew, Theodoros M. Bampouras, Hannah Young, et al.. (2020). The EX-FRAIL CKD trial: a study protocol for a pilot randomised controlled trial of a home-based EXercise programme for pre-frail and FRAIL, older adults with Chronic Kidney Disease. BMJ Open. 10(6). e035344–e035344. 10 indexed citations
7.
Nixon, Andrew, Theodoros M. Bampouras, Hannah Young, et al.. (2020). P0958THE EX-FRAIL CKD TRIAL: A PILOT RANDOMISED CONTROLLED TRIAL OF A HOME-BASED EXERCISE PROGRAMME FOR PRE-FRAIL AND FRAIL, OLDER ADULTS WITH CHRONIC KIDNEY DISEASE. Nephrology Dialysis Transplantation. 35(Supplement_3). 1 indexed citations
8.
Nixon, Andrew, Theodoros M. Bampouras, Neil Pendleton, et al.. (2020). Frailty is independently associated with worse health-related quality of life in chronic kidney disease: a secondary analysis of the Frailty Assessment in Chronic Kidney Disease study. Clinical Kidney Journal. 14(3). 1035–1035. 1 indexed citations
9.
Morris, Adam, Camilo L. M. Morais, Kássio M. G. Lima, et al.. (2020). A comparative analysis of different biofluids using Raman spectroscopy to determine disease activity in ANCA‐associated vasculitis. Journal of Biophotonics. 14(4). 4 indexed citations
10.
Nixon, Andrew, Theodoros M. Bampouras, Neil Pendleton, et al.. (2019). Frailty is independently associated with worse health-related quality of life in chronic kidney disease: a secondary analysis of the Frailty Assessment in Chronic Kidney Disease study. Clinical Kidney Journal. 13(1). 85–94. 47 indexed citations
11.
Huasen, Bella, et al.. (2019). Retroperitoneal fibrosis—the long and winding path. BJR|case reports. 6(2). 20190086–20190086. 2 indexed citations
12.
Brady, Mark E. & Donal O’Donoghue. (2011). Back to the Future: Changes in the Dialysis Delivery Model in the UK. Peritoneal Dialysis International. 31(2_suppl). 63–72. 3 indexed citations
13.
Gnanapragasam, Vincent J., Ian R. Logan, Mark E. Brady, et al.. (2003). Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer development. Oncogene. 22(16). 2466–2477. 171 indexed citations
14.
Gaughan, Luke, Mark E. Brady, Susan Cook, David E. Neal, & Craig Robson. (2001). Tip60 Is a Co-activator Specific for Class I Nuclear Hormone Receptors. Journal of Biological Chemistry. 276(50). 46841–46848. 80 indexed citations
15.
Brady, Mark E., et al.. (2000). Androgen Receptor Nuclear Translocation Is Facilitated by the f-Actin Cross-Linking Protein Filamin. Molecular Endocrinology. 14(10). 1618–1626. 127 indexed citations
16.
Brady, Mark E., Luke Gaughan, Ian Waite, et al.. (1999). Tip60 Is a Nuclear Hormone Receptor Coactivator. Journal of Biological Chemistry. 274(25). 17599–17604. 212 indexed citations
17.
Major, Glenn N., et al.. (1997). Evidence for ubiquitin-mediated degradation of the DNA repair enzyme for O6-methylguanine in non-tumour derived human cell and tissue extracts. Biochemical Society Transactions. 25(2). 359S–359S. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ulrich Tschulena Breakdown of academic impact, for papers by Stefano Mattarocci Breakdown of academic impact, for papers by Dany Gauthier Breakdown of academic impact, for papers by Kristine M. Wadosky Breakdown of academic impact, for papers by Kazutoshi Yamana Breakdown of academic impact, for papers by Hisaichi Fujii Breakdown of academic impact, for papers by Seiji Arai Breakdown of academic impact, for papers by Rakhshanda Layeequr Rahman Breakdown of academic impact, for papers by Verónica Rodríguez Breakdown of academic impact, for papers by Venke Skibeli
Rankless by CCL
2026